Education
About Us
Working with TipRanks
Follow Us
Iovance Biotherapeutics Inc (IOVA)
NASDAQ:IOVA
IOVA Stock Chart & Stats
Day’s Range― - ―
52-Week Range$2.70 - $14.23
Previous CloseN/A
Volume2.95M
Average Volume (3M)11.19M
Market Cap
$993.47M
Enterprise Value$1.99B
Total Cash (Recent Filing)$311.80K
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta2.24
Next Earnings
May 13, 2025EPS Estimate
-0.24Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.30
Shares Outstanding327,876,700
10 Day Avg. Volume9,996,399
30 Day Avg. Volume11,191,913
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)7.07
Price to Cash Flow (P/CF)-4.00
P/FCF Ratio0.00
Enterprise Value/Market Cap2.00
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit49.67
Enterprise Value/Ebitda-5.49
Forecast
1Y Price Target
$19.83Price Target Upside595.79% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering14
---
Iovance Biotherapeutics News
PremiumCompany Announcements
Iovance Biotherapeutics’ Earnings Call Highlights Growth and Challenges
PremiumCompany Announcements
Iovance Biotherapeutics Reports Strong 2024 Earnings---
Bulls Say, Bears Say
Bulls Say
Financial PositionIovance ended the quarter with a strong cash position of $403.8 million, supporting future growth initiatives.
Market OpportunitiesIovance Biotherapeutics is making significant progress with TIL therapy for endometrial cancer, a field with no currently approved therapies, representing a significant opportunity to address unmet medical needs.
Revenue PerformanceStrong Proleukin sales indicate rapid and sustained demand for AMTAGVI, suggesting potential growth in the upcoming year.
Bears Say
Market Adoption ChallengesThere are two schools of thought regarding the use of TIL, with some favoring later use due to side effects and complicated processes, which could impact adoption rates.
Revenue ConcernsThe stock is down approximately 20% post-close because of perceived Amtagvi revenue slowdown.
Revenue MissQ4 Amtagvi revenue of $49MM missed consensus of $55MM by 11%.
---
Ownership Overview
0.30% Insiders
16.72% Mutual Funds
33.12% Other Institutional Investors
34.21% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
IOVA FAQ
What was Iovance Biotherapeutics Inc’s price range in the past 12 months?
Iovance Biotherapeutics Inc lowest stock price was $2.70 and its highest was $14.23 in the past 12 months.
What is Iovance Biotherapeutics Inc’s market cap?
Iovance Biotherapeutics Inc’s market cap is $993.47M.
When is Iovance Biotherapeutics Inc’s upcoming earnings report date?
Iovance Biotherapeutics Inc’s upcoming earnings report date is May 13, 2025 which is in 33 days.
How were Iovance Biotherapeutics Inc’s earnings last quarter?
Iovance Biotherapeutics Inc released its earnings results on Feb 27, 2025. The company reported -$0.26 earnings per share for the quarter, beating the consensus estimate of -$0.268 by $0.008.
Is Iovance Biotherapeutics Inc overvalued?
According to Wall Street analysts Iovance Biotherapeutics Inc’s price is currently Undervalued.
Does Iovance Biotherapeutics Inc pay dividends?
Iovance Biotherapeutics Inc does not currently pay dividends.
What is Iovance Biotherapeutics Inc’s EPS estimate?
Iovance Biotherapeutics Inc’s EPS estimate is -0.24.
How many shares outstanding does Iovance Biotherapeutics Inc have?
Iovance Biotherapeutics Inc has 327,876,700 shares outstanding.
What happened to Iovance Biotherapeutics Inc’s price movement after its last earnings report?
Iovance Biotherapeutics Inc reported an EPS of -$0.26 in its last earnings report, beating expectations of -$0.268. Following the earnings report the stock price went down -19.392%.
Which hedge fund is a major shareholder of Iovance Biotherapeutics Inc?
Currently, no hedge funds are holding shares in IOVA
---
Iovance Biotherapeutics Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$19.83 (595.79% Upside)
$19.83 (595.79% Upside)
Blogger Sentiment
Bullish
IOVA Sentiment 75%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Decreased
By 4.6M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $503.0K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.4%
Last 30 Days ▼ 3.4%
Last 30 Days ▼ 3.4%
News Sentiment
Neutral
Bullish news 50%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-78.19%
12-Months-Change
Fundamentals
Return on Equity
-57.48%
Trailing 12-Months
Asset Growth
16.67%
Trailing 12-Months
Company Description
Iovance Biotherapeutics Inc
Iovance Biotherapeutics, Inc. is a biotechnology company focused on the development and commercialization of novel cancer immunotherapies based on tumor-infiltrating lymphocyte (TIL) technology. The company operates within the biotechnology and pharmaceuticals sectors, primarily targeting various forms of cancer. Iovance's core product candidates include lifileucel for the treatment of metastatic melanoma and LN-145 for the treatment of cervical cancer and other solid tumors.
---
IOVA Earnings Call
Q4 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call demonstrated strong revenue performance and positive market adoption for Amtagvi, with significant highlights in manufacturing capacity and pipeline progress. However, high operating costs and the need for acceleration in adoption at ATCs present challenges.Read More>---
IOVA Stock 12 Month Forecast
Average Price Target
$19.83
▲(595.79% Upside)
Technical Analysis
Pacira Pharmaceuticals
―
Ardelyx
―
Viridian Therapeutics
―
Syndax Pharmaceuticals
―
89bio
―
Best Analysts Covering IOVA
1 Year
1 Year Success Rate
15/33 ratings generated profit
1 Year Average Return
+16.36%
reiterated a buy rating last month
Copying Geulah Livshits's trades and holding each position for 1 Year would result in 45.45% of your transactions generating a profit, with an average return of +16.36% per trade.
---